Fenwick & West represented Invenra Inc. in its expanded collaboration with Exelixis, Inc. (Nasdaq: EXEL). Exelixis and Invenra had entered into a collaboration on May 2, 2018, to discover and develop multispecific antibodies through the use of Invenra’s B-BodyTMtechnology platform. The new collaboration will continue to use the Invenra antibody discovery capabilities to generate additional biologics-based programs.

More information about the collaboration can be obtained from Invenra’s announcement.

The Fenwick transaction team included technology transactions partner Stefano Quintini and licensing attorney Amy Manning.

Login

Don’t have an account yet?

Register